Rutgers, The State University of New Jersey
rutgers.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
491
Active
146
Phase 3
21
Total enrollment
159,713
Pipeline matrix
Showing 40 of 64 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Melatonin | — | — | — | — | 2 | ||
| Bupivacaine 0.5% Injectable Solution | — | — | — | — | — | 1 | |
| Ropivacaine 0.2% Injectable Solution | — | — | — | — | — | 1 | |
| 1.3% liposomal bupivacaine | — | — | — | — | — | 1 | |
| 1 month Rifapentine, Isoniazid and Vitamin B6 | — | — | — | — | — | 1 | |
| CeFAZolin 1000 MG | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 | |
| Xeloda | — | — | — | — | — | 1 | |
| Intranasal Insulin | — | — | — | — | 2 | ||
| bupivacaine liposome injectable suspension | — | — | — | — | — | 1 | |
| Bupivacaine Hydrochloride | — | — | — | — | — | 1 | |
| Intranasal Placebo | — | — | — | — | — | 1 | |
| opioid-containing analgesic | — | — | — | — | — | 1 | |
| two over-the-counter analgesics | — | — | — | — | — | 1 | |
| High Dose Buprenorphine | — | — | — | — | — | 1 | |
| Standard Buprenorphine Dose | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | 7 | ||
| Pembrolizumab | — | — | — | — | 6 | ||
| Paclitaxel | — | — | — | — | 5 | ||
| Temporo-masseteric Nerve Block | — | — | — | — | — | 2 | |
| Tirzepatide | — | — | — | — | — | 2 | |
| Capecitabine | — | — | — | — | — | 2 | |
| Docetaxel | — | — | — | — | — | 2 | |
| Sulforaphane | — | — | — | — | — | 1 | |
| Sulfasalazine | — | — | — | — | — | 1 | |
| Oral Pain Medications only | — | — | — | — | — | 1 | |
| pegylated liposomal doxorubicin hydrochloride | — | — | — | — | — | 1 | |
| epirubicin hydrochloride | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Trifluridine and Tipiracil Hydrochloride | — | — | — | — | — | 1 | |
| Superior laryngeal nerve block - Intervention | — | — | — | — | — | 1 | |
| Superior laryngeal nerve block - Placebo | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| 5Fluorouracil | — | — | — | — | — | 1 | |
| EXTERNAL BEAM RADIATION | — | — | — | — | — | 1 | |
| TAS-102, oxaliplatin, irinotecan with bevacizumab | — | — | — | — | — | 1 | |
| Four week alternating FOLFOX and FOLFIRI | — | — | — | — | — | 1 | |
| Temporomasseteric Nerve Block | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 |
24 more active programs hidden
Next readouts
- 2021-02-08
- 2023-07-07
- 2024-03-27
- 2024-11-24
- 2025-12
- 2026-01-16
- 2026-05-01
- 2026-06
- 2026-06
- 2026-06-30
Top conditions
- Breast Cancer15
- Prostate Cancer13
- Autism Spectrum Disorder10
- Depression9
- Anxiety8
- Parkinson Disease8
- Opioid Use8
- Healthy7
Frequently asked questions about Rutgers, The State University of New Jersey
- How many clinical trials does Rutgers, The State University of New Jersey have on ClinicalTrials.gov?
- Rutgers, The State University of New Jersey is listed as the lead sponsor on 491 clinical trials in ClinicalTrials.gov, 146 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Rutgers, The State University of New Jersey's trials are in Phase 3?
- 21 of Rutgers, The State University of New Jersey's trials are in Phase 3, spread across 64 active drug programs.
- What therapeutic areas does Rutgers, The State University of New Jersey focus on?
- Rutgers, The State University of New Jersey's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Autism Spectrum Disorder, Depression, Anxiety.
- When are Rutgers, The State University of New Jersey's next clinical trial readouts?
- Rutgers, The State University of New Jersey has 10 upcoming primary-completion readouts tracked here; the soonest is “Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer”, expected around 2021-02-08.